Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C | P18825 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | GLA | P06280 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7139664 | 0.89 | ADRA2C (0.51) | ADRA2CHDAC3HDAC4HDAC1HDAC2 | |
| SCHEMBL5742511 | 0.84 | ADRA2C (0.54) | ADRA2CSMN1; SMN2MEN1KMT2ACYP3A4 | |
| SCHEMBL7791465 | 0.83 | HDAC3 (0.51) | ADRA2CHDAC3HDAC4HDAC1HDAC2 | |
| SCHEMBL28647892 | 0.83 | ALDH1A1 (0.50) | ADRA2CSMN1; SMN2MEN1KMT2ACYP3A4 | |
| SCHEMBL5682214 | 0.82 | HTT (0.49) | ADRA2CSMN1; SMN2MEN1KMT2ACYP3A4 | |
| SCHEMBL6261729 | 0.82 | TP53 (0.58) | ADRA2CSMN1; SMN2MEN1KMT2ACYP3A4 | |
| SCHEMBL20180510 | 0.82 | TP53 (0.49) | ADRA2CSMN1; SMN2MEN1KMT2ACYP3A4 | |
| SCHEMBL27559930 | 0.82 | SMN1; SMN2 (0.48) | ADRA2CSMN1; SMN2MEN1KMT2ACYP3A4 | |
| SCHEMBL10526462 | 0.81 | ALDH1A1 (0.52) | ADRA2CSMN1; SMN2MEN1KMT2ACYP3A4 | |
| SCHEMBL16278131 | 0.81 | MLYCD (0.34) | ADRA2CHDAC3HDAC4HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2895526-B1 | BRANCHED POLYAMINES FOR DELIVERY OF BIOLOGICALLY ACTIVE MATERIALS | IBM (US) | 2020-03-25 | — | — | EP | disclosed |
| EP-2516502-B1 | BIODEGRADABLE BLOCK POLYMERS FOR DRUG DELIVERY, AND METHODS RELATED THERETO | IBM (US) | 2019-05-15 | — | — | EP | disclosed |
| CN-104769011-B | Branched polyamines for delivery of bioactive materials | 囯际商业机器公司 | 2017-04-19 | — | — | CN | disclosed |
| CN-104755534-B | Low molecular weight branched polyamines for delivery of bioactive materials | 囯际商业机器公司 | 2017-03-08 | — | — | CN | disclosed |
| US-9399044-B2 | Antimicrobial cationic polyamines | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2016-07-26 | — | — | US | disclosed |
| US-20150342984-A1 | ANTIMICROBIAL CATIONIC POLYAMINES | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2015-12-03 | — | — | US | disclosed |
| US-9109087-B2 | Low molecular weight branched polyamines for delivery of biologically active materials | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2015-08-18 | — | — | US | disclosed |
| EP-2895526-A1 | BRANCHED POLYAMINES FOR DELIVERY OF BIOLOGICALLY ACTIVE MATERIALS | International Business Machines Corporation (US) | 2015-07-22 | — | — | EP | disclosed |
| EP-2895527-A1 | LOW MOLECULAR WEIGHT BRANCHED POLYAMINES FOR DELIVERY OF BIOLOGICALLY ACTIVE MATERIALS | International Business Machines Corporation (US) | 2015-07-22 | — | — | EP | disclosed |
| CN-104769011-A | Branched polyamines for delivery of bioactive materials | IBM | 2015-07-08 | — | — | CN | disclosed |
| CN-102770477-A | Biodegradable block polymers for drug delivery, and methods related thereto | IBM | 2012-11-07 | — | — | CN | disclosed |
| EP-2516502-A1 | BIODEGRADABLE BLOCK POLYMERS FOR DRUG DELIVERY, AND METHODS RELATED THERETO | International Business Machines Corporation (US) | 2012-10-31 | — | — | EP | disclosed |
| US-20120231060-A1 | ANTIMICROBIAL HYDROGELS, METHODS OF PREPARATION THEREOF, AND ARTICLES THEREFROM | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH | 2012-09-13 | — | — | US | disclosed |
| US-8129371-B2 | Thienopyrimidine and pyrazolopyrimidine compounds and their use as mTOR kinase and PI3 kinase inhibitors | WYETH LLC (US) | 2012-03-06 | — | — | US | disclosed |
| WO-2011078803-A1 | BIODEGRADABLE BLOCK POLYMERS FOR DRUG DELIVERY, AND METHODS RELATED THERETO | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2011-06-30 | — | — | WO | disclosed |
| US-20110152167-A1 | BIODEGRADABLE BLOCK POLYMERS FOR DRUG DELIVERY, AND METHODS RELATED THERETO | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2011-06-23 | — | — | US | disclosed |
| US-20090098086-A1 | THIENOPYRIMIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | WYETH (US) | 2009-04-16 | — | — | US | disclosed |
| EP-1750704-A2 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | Bristol-Myers Squibb Company (US) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005113537-A2 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-01 | — | — | WO | disclosed |
| CN-1455767-A | Substituted phenylcyclohexane carboxylic acid amides and use thereof | BAYER AG (DE) | 2003-11-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090098086-A1 | THIENOPYRIMIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | MTOR, PIK3CA, PIK3CD | ADRA2C 4004/4885HDAC3 1305/4885HDAC4 1184/4885 |
| US-20150342984-A1 | ANTIMICROBIAL CATIONIC POLYAMINES | ARG1, PARG, ARG2 | ADRA2C 3627/4885HDAC3 1399/4885HDAC4 611/4885 |
| US-20110152167-A1 | BIODEGRADABLE BLOCK POLYMERS FOR DRUG DELIVERY, AND METHODS RELATED THERETO | SAMM50, ADRM1, UFM1 | ADRA2C 2756/4885HDAC3 3740/4885HDAC4 3608/4885 |
| US-20120231060-A1 | ANTIMICROBIAL HYDROGELS, METHODS OF PREPARATION THEREOF, AND ARTICLES THEREFROM | CLTB, ITGAM, PICALM | ADRA2C 3606/4885HDAC3 3089/4885HDAC4 3557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.